# Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

> **NCT02384759** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 117 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** aflibercept
- **DRUG:** LV5FU2

## Key facts

- **NCT ID:** NCT02384759
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02384759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02384759, "Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02384759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*